tiprankstipranks
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price & Analysis

970 Followers

MDGL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$119.76 - $322.67
Previous Close$212.04
Volume625.15K
Average Volume (3M)570.23K
Market Cap
$4.67B
Enterprise Value$4.55B
Total Cash (Recent Filing)$232.35M
Total Debt (Recent Filing)$116.56M
Price to Earnings (P/E)-10.6
Beta1.00
May 07, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.93
Shares Outstanding19,897,425
10 Day Avg. Volume268,582
30 Day Avg. Volume570,233
Standard Deviation0.44
R-Squared0.00320
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)11.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.65
Forecast
Price Target Upside84.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say
Competitive AdvantageWith physicians planning to prescribe Rezdiffra to over half of their patients, it challenges the dominance of competing drugs and underscores the strong sales potential of Rezdiffra in the NASH market.
Drug Approval And Market PotentialRezdiffra is now available in the US as the first and only approved therapy to treat nonalcoholic steatohepatitis (NASH), potentially addressing a significant market of approximately 315,000 patients.
Sales And Market PenetrationAnalysts anticipate robust commercial coverage for Rezdiffra, expecting to reach around 80% of lives covered by year-end, which could significantly drive sales upward.
Bears Say
Financial PerformanceManagement expects a gradual launch for Rezdiffra and anticipates that the Gross-to-Net (GTN) adjustments will be choppy and normalize over time, suggesting potential initial volatility in revenue recognition.
Market Access ChallengesPayers are expected to implement rigorous coverage guidelines for resmetirom, potentially slowing patient access.
Pricing ConcernsThe $47k per patient per year price tag for Rezdiffra is at the higher end of cost-effectiveness analyses, which could result in commercial barriers.
---

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

MDGL FAQ

What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $119.76 and its highest was $322.67 in the past 12 months.
    What is Madrigal Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
    Madrigal Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2024 which is in 17 days.
      How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
      Madrigal Pharmaceuticals Inc released its earnings results on Feb 28, 2024. The company reported -$5.68 earnings per share for the quarter, missing the consensus estimate of -$5.239 by -$0.441.
        Is Madrigal Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Madrigal Pharmaceuticals Inc pay dividends?
          Madrigal Pharmaceuticals Inc does not currently pay dividends.
          What is Madrigal Pharmaceuticals Inc’s EPS estimate?
          Madrigal Pharmaceuticals Inc’s EPS estimate is -$6.23.
            How many shares outstanding does Madrigal Pharmaceuticals Inc have?
            Madrigal Pharmaceuticals Inc has 20,993,578 shares outstanding.
              What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
              Madrigal Pharmaceuticals Inc reported an EPS of -$5.68 in its last earnings report, missing expectations of -$5.239. Following the earnings report the stock price went up 6.018%.
                Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
                Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 456M.
                  ---

                  Company Description

                  Madrigal Pharmaceuticals Inc

                  Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
                  ---

                  MDGL Stock 12 Months Forecast

                  Average Price Target

                  $391.14
                  ▲(84.47% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"139":"$139","566":"$566","245.75":"$245.8","352.5":"$352.5","459.25":"$459.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":565,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$565.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":391.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$391.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$270.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[139,245.75,352.5,459.25,566],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.04,267.80615384615385,292.5723076923077,317.3384615384615,342.1046153846154,366.87076923076927,391.63692307692304,416.4030769230769,441.1692307692308,465.93538461538463,490.70153846153846,515.4676923076923,540.2338461538461,{"y":565,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.04,254.4323076923077,265.82461538461536,277.2169230769231,288.60923076923075,300.0015384615385,311.39384615384614,322.78615384615387,334.17846153846153,345.5707692307692,356.9630769230769,368.3553846153846,379.7476923076923,{"y":391.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,243.04,245.11384615384614,247.1876923076923,249.26153846153846,251.3353846153846,253.40923076923076,255.4830769230769,257.55692307692306,259.6307692307692,261.7046153846154,263.77846153846156,265.8523076923077,267.92615384615385,{"y":270,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":239.79,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.37,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":259.94,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.13,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.48,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.14,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.88,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.89,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.12,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.28,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.28,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.63,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.04,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Amarin
                  Arrowhead Pharmaceuticals
                  Corbus Pharmaceuticals
                  Galmed Pharmaceuticals

                  Best Analysts Covering MDGL

                  1 Year
                  Liisa BaykoEvercore ISI
                  1 Year Success Rate
                  8/15 ratings generated profit
                  53%
                  1 Year Average Return
                  +113.28%
                  reiterated a buy rating last month
                  Copying Liisa Bayko's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +113.28% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis